Arthralgias and myalgias related to quinupristin-dalfopristin administration.
This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.
Olsen
K M
KM
Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6045, USA. kolsen@unmc.edu
Rebuck
J A
JA
Rupp
M E
ME
D018771:Arthralgia / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced* / Q000175:diagnosis; D010146:Pain / Q000139:chemically induced; D012189:Retrospective Studies; D012307:Risk Factors; D014769:Virginiamycin / Q000009:adverse effects*
D014769:Virginiamycin; C062940:quinupristin-dalfopristin